New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
11:33 EDTMU, APOL, INFY, PCYC, SVUOptions with decreasing implied volatility: APOL SVU INFY MU PCYC
News For APOL;SVU;INFY;MU;PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 28, 2015
08:13 EDTSVUMoneyGram renews longstanding agreement with Supervalu
Subscribe for More Information
07:19 EDTMUCowen to hold a conference
43rd Annual Technology, Media & Telecom Conference is being held in New York on May 27-28 with webcasted company presentations to begin on May 28 at 8 am; not all company presentations may be webcasted. Webcast Link
May 27, 2015
16:03 EDTMUOptions Update; May 27, 2015
iPath S&P 500 VIX Short-Term Futures down 82c to 18.56 Option volume leaders: AAPL KORS BRCM MCD FB MNKD AAL YHOO BAC MU ANF S EOX
07:07 EDTMUJefferies recommends buying shares of Micron
Subscribe for More Information
May 26, 2015
09:03 EDTPCYCRosetta announces selection of first pilot project grant under MCC alliance
Rosetta Genomics (ROSG) announces the selection of the first project grant under its strategic alliance with Moffitt Cancer Center. The funded project is titled, “miRNAs as Determinants and Predictors of Ibrutinib Resistance in Mantle Cell Lymphoma.” The project will be led by Jianguo Tao, M.D., Ph.D., a renowned hematopathologist and physician-scientist at the Molecular and Chemical Biology Program at Moffitt, and Bijal Shah, M.D., an oncologist in the Experimental Therapeutic Program at Moffitt. MCL is an aggressive B-cell lymphoma. Ibrutinib, a blockbuster pharmaceutical marketed by Pharmacyclics (PCYC) under the brand name of IMBRUVICA, is a novel Bruton's tyrosine kinase inhibitor that received U.S. Food and Drug Administration approval for the treatment of MCL in 2014, with high response rates reported in patients with MCL. However, many MCL patients who initially show a partial or complete response to ibrutinib, eventually develop ibrutinib-acquired drug resistance accompanied by fulminant progression and accelerated mortality. Studies conducted by Drs. Tao and Shah have suggested that microRNAs play a role in the development of resistance to ibrutinib. The goal of this funded project is to further explore the role and underlying molecular mechanism of microRNAs in ibrutinib resistance in MCL, for development of microRNA-based predictive biomarkers for ibrutinib therapy, as well as for a rational design to overcome drug resistance.
08:32 EDTPCYCAbbVie completes acquisition of Pharmacyclics
Subscribe for More Information
May 22, 2015
10:38 EDTMUMizuho says buy NXP, Micron, ON Semi
Mizuho Securities initiated coverage of a number of chip makers in a note to investors last night. Among its recommendation in the space, NXP Semiconductors (NXPI), Micron (MU), and ON Semiconductor (ON) were called out with Buy ratings. NXP: NXP Semiconductors dominates the mobile payment market with its NFC products, Mizuho analyst Vijay Rakesh wrote. The company's NFC chips are used in Apple's (AAPL) Apple Pay and NXP has a strong mobile payment ecosystem in China, the analyst explained. NXP Semiconductors is also a leader in providing chips used to enhance credit card security, as its Chip+Pin system has a 75% share of the global market and is in the process of being deployed in the U.S, according to Rakesh. Going forward, NXP's growth should be driven by the automotive products of Freescale, which the company acquired earlier this year, the analyst stated, adding that NXP should derive strong synergies and cash flow from the deal. He set a $140 price target on the stock. MICRON: Sales of flash memory device maker Micron's DRAM products should be boosted by a PC rebound in the second half of this year, according to Rakesh. Additionally, the company's new CFO could make its actions more predictable, pleasing investors, the analyst stated. ON: ON Semiconductor should benefit from its acquisition of Aptina, which gave ON a significant presence in the Advanced Driver Assistance Systems, or ADAS, market, Rakesh believes. ADAS is likely to grow rapidly around the world, driven by mandates, the analyst predicted. A second positive catalyst for ON will be the proliferation of wireless charging, added the analyst, who set a $16 price target on the shares. PRICE ACTION: In early trading, NXP rose nearly 1% to trade nearly $108, Micron gained 2.6% to $27.61, and ON was fractionally higher. Other semiconductor makers initiated with Buy ratings by the firm include Skyworks (SWKS), Synaptics (SYNA), Avago (AVGO) and Cypress Semiconductor (CY).
09:58 EDTMUOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Allison Transmission (ALSN) initiated with a Buy at Stifel... Avago (AVGO) initiated with a Buy at Mizuho... Blackstone (BX) initiated with a Positive at Susquehanna... Cellectis (CLLS) initiated with an Outperform at Oppenheimer... Cypress Semiconductor (CY) initiated with a Buy at Mizuho... Esperion (ESPR) initiated with a Sell at Chardan... H&R Block (HRB) initiated with an Overweight at Piper Jaffray... Horizon Pharma (HZNP) initiated with an Outperform at Leerink... M/A-COM (MTSI) initiated with a Buy at Goldman... Meritor (MTOR) initiated with a Hold at Stifel... Micron (MU) initiated with a Buy at Mizuho... Monster Worldwide (MWW) initiated with a Neutral at Piper Jaffray... NXP Semiconductors (NXPI) initiated with a Buy at Mizuho... National Storage (NSA) initiated with a Sector Weight at KeyBanc... ON Semiconductor (ON) initiated with a Buy at Mizuho... Qorvo (QRVO) initiated with a Buy at Goldman... SanDisk (SNDK) initiated with a Neutral at Mizuho... Sharps Compliance (SMED) initiated with a Buy at Stifel... Skyworks (SWKS) initiated with a Buy at Mizuho... StemCells (STEM) initiated with a Buy at Cantor... Synaptics (SYNA) initiated with a Buy at Mizuho... Synergy Pharmaceuticals (SGYP) initiated with a Buy at Canaccord... Texas Instruments (TXN) initiated with a Neutral at Mizuho... TriNet (TNET) initiated with a Neutral at Piper Jaffray... Vascular Biogenics (VBLT) initiated with a Buy at Roth Capital... Verifone (PAY) initiated with an Outperform at Imperial Capital... uniQure (QURE) initiated with an Outperform at Oppenheimer.
09:34 EDTMUActive equity options trading on open
Active equity options trading on open: AAPL BABA AMZN FB MU BIDU SDRL BAC INTC EXPE CHK FEYE
08:06 EDTPCYCPharmacyclics announces positive opinion from EMA for Imbruvica
Subscribe for More Information
08:00 EDTPCYCAbbVie announces expiration of HSR waiting period for Pharmacyclics acquisition
AbbVie (ABBV) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of Pharmacyclics (PCYC) has expired today. The expiration satisfies the exchange offer condition with respect to the approvals and clearances required under antitrust laws. Assuming that the other customary exchange offer conditions are satisfied, including a minimum tender of at least a majority of outstanding Pharmacyclics shares, it is expected that the exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics will expire today at 5:00 p.m., New York City time, without any further extension.
May 21, 2015
16:08 EDTMUMicron initiated with a Buy at Mizuho
Subscribe for More Information
08:04 EDTPCYCAbbVie announces offer consideration for acquisition of Pharmacyclics
AbbVie (ABBV) announced the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics (PCYC) for a mix of cash and AbbVie common stock, as described in the Registration Statement on Form S-4 filed with the SEC by AbbVie on March 23, 2015, as amended. The mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie common stock.
May 20, 2015
16:00 EDTMUOptions Update; May 20, 2015
iPath S&P 500 VIX Short-Term Futures up 3c to 19.19. Option volume leaders: AAPL AAL YHOO DAL FB BABA UAL BAC TWTR LUV C TSLA GE MU
09:07 EDTPCYCJohnson & Johnson says exploring eight new indications for Imbruvica
Imbruvica is jointly developed and commercialized by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ) subsidiary Janssen Biotech. AbbVie (ABBV) is in the process of acquiring Pharmacyclics.
07:36 EDTMUMicron estimates, target lowered on PC weakness at Deutsche Bank
Deutsche Bank lowered estimates for Micron after its channel checks indicated DRAM price negotiations "remain challenging" in May given amid soft PC demand. The firm, however, believes PC demand will strengthen starting in July driven by seasonality and the launch of Windows 10. It thinks this will be the last cut to estimates and maintains a Buy rating on Micron. It lowered its price target for shares to $32 from $34.
May 18, 2015
16:00 EDTMUOptions Update; May 18, 2015
Subscribe for More Information
10:57 EDTMUMicron May weekly calls active
Micron May weekly 26.5 and 27 weekly calls are active on total call volume of 35K contracts (3K puts). May weekly call option implied volatility is at 36, June is at 32, July is at 34; compared to its 90-day average of 35, active call volume suggests traders taking positions for large near term price movement.
10:32 EDTMUMicron management to meet with JMP Securities
Subscribe for More Information
May 17, 2015
15:07 EDTINFYInfosys likely to spend cash on acquisitions rather than returns, Barron's says
Infosys is likely to spend its capital on additional acquisitions rather than shareholder returns, Barron's contends in its 'International Trader - Asia' column. Barron's notes that the company has targeted an 18% annualized rate of revenue growth and looks to deepen its presence in social, mobile, "big data," and cloud through buyouts. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use